Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Inovio Pharmaceuticals clinical trials
Also known as Genetronics.
The registry lists 35 studies whose lead sponsor is Inovio Pharmaceuticals or one of 1 company grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 22, 2026.
Registry sponsor names on this page
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Inovio Pharmaceuticals.
- Inovio Pharmaceuticals31 studiesSame company
Something wrong?
- VGX Pharmaceuticals, LLC4 studies →Acquired — became part of Inovio Pharmaceuticals, Jun 1, 2009 · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 35 of 35.
- INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)Active, not recruitingNCT03491683Phase 1/2
- INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial CarcinomaCompletedNCT03502785Phase 1/2
- INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)CompletedNCT04398433Phase 1/2
- Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy VolunteersCompletedNCT04588428Phase 2
- REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)CompletedNCT03721978Phase 3
- Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 ExposureTerminatedNCT04642638Phase 2/3
- Evaluation of VGX-3100 and Electroporation Alone or in Combination With Imiquimod for the Treatment of HPV-16 and/or HPV-18 Related Vulvar HSIL (Also Referred as: VIN 2 or VIN 3)CompletedNCT03180684Phase 2
- REVEAL 1 (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)CompletedNCT03185013Phase 3
- VGX-3100 Delivered Intramuscularly (IM) Followed by Electroporation (EP) for the Treatment of HPV-16 and/or HPV-18 Related Anal or Anal/Peri-Anal, High Grade Squamous Intraepithelial Lesion (HSIL) in Individuals Seronegative for Human Immunodeficiency Virus (HIV)-1/2CompletedNCT03499795Phase 2
- Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in GhanaCompletedNCT04093076Phase 1
- Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy VolunteersWithdrawnNCT05430958Phase 1
- Safety, Tolerability and Immunogenicity of INO-4800 for COVID-19 in Healthy VolunteersCompletedNCT04336410Phase 1
- Medpulser Electroporation With Bleomycin Study to Treat Anterior Head and Neck Squamous Cell CarcinomaTerminatedNCT00198315Phase 3
- Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell CarcinomaTerminatedNCT00198328Phase 3
- A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical CancerCompletedNCT02172911Phase 1/2
- Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell CarcinomaCompletedNCT02163057Phase 1/2
- Safety, Tolerability and Immunogenicity of INO-4500 in Healthy VolunteersCompletedNCT03805984Phase 1
- Phase I Study of INO-1800 With or Without INO-9112 + EP in Chronic Hepatitis B SubjectsCompletedNCT02431312Phase 1
- Open-Label Study of INO-4212 With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy VolunteersCompletedNCT02464670Phase 1
- hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of RelapseCompletedNCT02960594Phase 1
- Immunotherapy in Subjects With HPV-6 Associated Aerodigestive Precancerous Lesions and MalignanciesCompletedNCT02241369Phase 1
- A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3CompletedNCT01304524Phase 2
- Fourth Dose of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + EP in Adult Females Previously Vaccinated With Three Doses of VGX-3100CompletedNCT01188850Phase 1
- Trial to Evaluate Safety and Immunogenicity of INO-5150 Alone or With INO-9012 in Men With Prostate CancerCompletedNCT02514213Phase 1
- Study Using the MedPulser Electroporation System With Bleomycin to Treat Cutaneous and Subcutaneous CancerCompletedNCT00198276Phase 4
- Study Using the Medpulser Electroporation System With Bleomycin to Treat Head and Neck CancerCompletedNCT00198263Phase 4
- Study of VGX-3400X, H5N1 Avian Influenza Virus DNA Plasmid + Electroporation in Healthy AdultsCompletedNCT01142362Phase 1
- Phase I of Human Papillomavirus (HPV) DNA Plasmid (VGX-3100) + Electroporation for CIN 2 or 3CompletedNCT00685412Phase 1
- A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001CompletedNCT01403155Phase 1
- A Study of DNA Vaccine With Electroporation for the Prevention of Disease Caused by H1 and H5 Influenza VirusCompletedNCT01405885Phase 1
- Study of PENNVAX™-B (Gag, Pol, Env) + Electroporation in HIV-1 Infected Adult ParticipantsCompletedNCT01082692Phase 1
- Antiviral Activity and Safety of Mifepristone at 2 Doses in HIV-1 Infected SubjectsCompletedNCT00352911Phase 2
Sponsor listed in the registry: VGX Pharmaceuticals, LLC · First submitted before VGX Pharmaceuticals, LLC became part of Inovio Pharmaceuticals
- Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected PatientsCompletedNCT00255177Phase 2
Sponsor listed in the registry: VGX Pharmaceuticals, LLC · First submitted before VGX Pharmaceuticals, LLC became part of Inovio Pharmaceuticals
- Multiple-Dose Study of VGX-1027 in Healthy SubjectsCompletedNCT00760396Phase 1
Sponsor listed in the registry: VGX Pharmaceuticals, LLC · First submitted before VGX Pharmaceuticals, LLC became part of Inovio Pharmaceuticals
- Phase I Safety and Pharmacokinetic Study of VGX-1027 in Healthy SubjectsCompletedNCT00627120Phase 1
Sponsor listed in the registry: VGX Pharmaceuticals, LLC · First submitted before VGX Pharmaceuticals, LLC became part of Inovio Pharmaceuticals